utilización del bevacizumab en la neovascularización corneal use of bevacizumab in corneal neovascularization

Clicks: 271
ID: 194096
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 24 articles by views in journal of the chinese chemical society

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
La neovascularización corneal es causa de pérdida de su transparencia y también es un factor de riesgo para el rechazo secundario de trasplantes en esa estructura. El bevacizumab es un anticuerpo monoclonal humanizado que bloquea selectivamente la cascada de formación del VEGF y con esto disminuye la formación de vasos sanguíneos. Se presentan tres casos con neovascularización corneal por diferentes causas, a los cuales se le administró tres dosis subconjuntival de 2,5 mg de bevacizumab, con una frecuencia mensual. En los ojos tratados se observó una regresión parcial de la neovascularización corneal y fue más visible en el paciente con antecedente de quemadura corneal.
Neovascularization of the cornea is a cause of loss of transparency of the same and is also a risk factor for secondary rejection corneal transplants. Bevacizumab is a humanized monoclonal antibody that selectively blocks the formation of the VEGF cascade and, with this, decreases the formation of blood vessels. Three cases with corneal neovascularization from different causes were presented, which were given three doses of 2.5 mg subconjunctival bevacizumab once a month. A partial regression of corneal neovascularization was observed in the treated eyes, being more visible in the patient with a history of corneal burn.
Reference Key
daz2012revistautilizacin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Taimi Cárdenas Díaz;Rosario Torres Ortegas;Yeni Corcho Arévalo;Dunia Cruz Izquierdo;Armando Capote Cabrera;María del Carmen Benítez Meriño
Journal journal of the chinese chemical society
Year 2012
DOI
DOI not found
URL
http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762012000200017
Keywords
bevacizumab

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.